Open-Label Extension Study of Setmelanotide

NCT06596135 · clinicaltrials.gov ↗

PHASE3

Phase

ENROLLING_BY_INVITATION

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Obesity Associated With Defects in Leptin-melanocortin Pathway

Interventions

DRUG: Setmelanotide

Sponsor

Rhythm Pharmaceuticals, Inc.